Odyssey Math Tuition offers H2 Math online courses for JC 1 and JC 2 students in Singapore, featuring a proprietary ...
Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across ...
In the Phase III results presented and published today, olezarsen demonstrated rapid, substantial and significant reductions in triglycerides by up to 72% on top of standard of care and reduced the ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
GRAIL, Inc. , a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
This quarter introduced new opportunities while reinforcing the broadening appeal of some of our mainstay technologies,” said P. Peter Pascali, President and CEO of PyroGenesis Inc. “The $1.2 million ...
Opinion
The Pioneer on MSNOpinion

Delhi chokes as citizens cry for breath

It may shock outsiders, but for Delhiites this is an annual recurrence. The air is thick with smog, and breathing it is a daily torment. What would be declared a medical emergency in many countries ...
According to data from the Gauteng Department of Health, between 1 January and 31 October 2025, a total of 48 typhoid fever cases were documented in the Tshwane district.
AI-enabled search is shifting discovery from keyword matching to intent and context. This means marketers must now structure ...
During the 6 months after treatment to restore a normal heart rhythm, adults with atrial fibrillation (AFib) who were ...
BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ ...